Archived explainer. For the current picture see today's SLS page.
Why Is SELLAS LIFE SCIENCES (SLS) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 31, 2026 at 10:54 AM ET · reviewed against 2 wire stories
SELLAS LIFE SCIENCES (SLS) is drawing unusual attention today. Our newswire has captured 2 stories on SLS across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
SLS stock is moving today after opening with a 2.6% gap up from Friday’s close of $13.21. The stock briefly climbed to a session high of $13.88 before retreating to $13.13 in early afternoon trading. The move follows a period of volatility and uncertainty over the company’s AML drug candidate and the upcoming release of pivotal trial data.
What Happened
On Monday, Sellas Life Sciences CEO Angelos Stergiou posted on LinkedIn that the company will let the data from its pivotal AML trial "speak for itself" as the REGAL catalyst nears. The CEO described the data as "rigorous" and "unblinded," suggesting the results will carry significant weight. This statement came after Friday’s 13.15% drop in SLS shares, which traders attributed to the company’s silence on its AML drug candidate. The recent volatility reflects investor uncertainty and speculation about the trial’s outcome.
What The Data Shows
The stock opened at $13.55, a 2.6% gap up from the prior close, but quickly lost ground, reaching a session low of $13.05. Trading volume of 2.1 million shares so far is below the 3-month average. Over the last 8 sessions, the stock has moved up 15.7%, from $13.10 to $15.15. The 52-week range is $1.39 to $15.88, and the stock has printed 5 fresh 52-week highs and 2 fresh 52-week lows on August 31, 2026. Retail chatter on r/wallstreetbets includes a single post thanking the stock, indicating limited retail engagement.
What To Watch
Investors should continue to monitor the release of data from the pivotal AML trial, which is expected to serve as a key catalyst for the stock. No earnings date is currently scheduled, but coverage breadth and analyst commentary will be important to track as the trial nears.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SLS · Aug 31 session (5-min) · +0.91% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 2 stories · 46/100 neutral
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
12d agoStocktwits NewsBULLISH 58Product/PR
Sellas CEO Stergiou Says ‘Rigorous, Unblinded’ Data From Pivotal AML Trial Will 'Speak For Itself' As REGAL Catalyst Nears
In a post on LinkedIn on Monday, Angelos Stergiou said despite speculation and outside commentary ‘naturally’ increasing, the company will let the data speak for itself.
15d agoYahoo TopBEARISH 34General
Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate
Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment candidate for acute myeloid leukemia (AML). The drop was triggered by a report from a Germany-based news site that the company has already hit […]
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →